• Ionis Pharmaceuticals recently announced that the FDA has accepted for Priority Review its New Drug Application for zilganersen, an investigational RNA-targeted therapy for the rare and often fatal neurological disorder Alexander disease, based on a pivotal study showing clinically meaningful stabilization in gait speed and supportive safety data.
• This milestone underscores Ionis’s ability to advance antisense oligonucleotide medicines into late-stage regulatory review for ultra-rare neurological conditions, potentially expanding its rare-disease franchise and reinforcing its RNA-targeted platform.
• We’ll now examine how the FDA’s Priority Review for zilganersen, and its promising pivotal data, could reshape Ionis’s broader investment narrative.

We've uncovered the 12 dividend fortresses yielding 5%+ that don't just survive market storms, but thrive in them.

Ionis Pharmaceuticals Investment Narrative Recap

To own Ionis, you need to believe its RNA platform and late stage assets like olezarsen and donidalorsen can eventually support profitable growth despite today’s losses and premium valuation. The FDA’s Priority Review for zilganersen adds another potential rare disease revenue stream, but the most important near term catalyst still sits with olezarsen’s June 30, 2026 PDUFA, while execution and pricing around expanding its triglyceride franchise remain the central risks.

Among recent announcements, the FDA’s acceptance of olezarsen’s sHTG filing with a June 30, 2026 PDUFA date is most relevant, because it highlights Ionis’s dependence on multiple late stage regulatory decisions in a short window. When viewed alongside zilganersen’s accelerated path, you get a clearer picture of how concentrated Ionis’s catalyst calendar has become and how any delay or restrictive label across these programs could affect revenue visibility.

Yet behind these promising approvals, investors should also be aware that...

Ionis Pharmaceuticals' narrative projects $1.8 billion revenue and $18.8 million earnings by 2029. This requires 25.0% yearly revenue growth and a $400.2 million earnings increase from -$381.4 million today.

Uncover how Ionis Pharmaceuticals' forecasts yield a $93.90 fair value, a 30% upside to its current price.

Exploring Other Perspectives

Before this news, the most optimistic analysts were assuming Ionis could reach about US$2.0 billion of revenue and US$374 million of earnings by 2028, so if you lean toward that bullish view on late stage approvals and pricing, zilganersen’s Priority Review may reinforce your thesis, while others may see it as increasing the same regulatory and execution risks you should be weighing carefully.

Explore 4 other fair value estimates on Ionis Pharmaceuticals - why the stock might be worth over 3x more than the current price!

Reach Your Own Conclusion

Disagree with existing narratives? Extraordinary investment returns rarely come from following the herd, so go with your instincts.

• A great starting point for your Ionis Pharmaceuticals research is our analysis highlighting 2 key rewards and 1 important warning sign that could impact your investment decision.
• Our free Ionis Pharmaceuticals research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate Ionis Pharmaceuticals' overall financial health at a glance.

Contemplating Other Strategies?

Don't miss your shot at the next 10-bagger. Our latest stock picks just dropped:

• AI is about to change healthcare. These 34 stocks are working on everything from early diagnostics to drug discovery. The best part - they are all under $10b in market cap - there's still time to get in early.
• Rare earth metals are an input to most high-tech devices, military and defence systems and electric vehicles. The global race is on to secure supply of these critical minerals. Beat the pack to uncover the 26 best rare earth metal stocks of the very few that mine this essential strategic resource.
• Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.